Genmab — Oktober 2018
-
God morgen

-
God morgen.

-
Så er smileyen tilbage hos Helge. Det lover godt for dagens marked

-

-
Tisotumab Vedotin (TV) Program Highlights
•Phase 1/2 Data Presented at ESMO: Seattle Genetics and Genmabreported updated data from the cervical cancer expansion cohort of theinnovaTV 201 phase 1/2 trial at the European Society for MedicalOncology 2018 Congress. The data continue to support the rationale forthe ongoing potentially pivotal trial, innovaTV 204, evaluating TV asmonotherapy for patients with recurrent and/or metastatic cervicalcancer who have relapsed or progressed after standard of -
-
from Earnings Conference Call Transcript: https://www.fool.com/earnings/call-transcripts/2018/10/26/seattle-genetics-inc-sgen-q3-2018-earnings-confere.aspx
-
Now I'll turn to Tisotumab Vedotin or TV which we're developing with Genmab. TV targets tissue factor which is expressed in a wide array of solid tumors. We are currently enrolling a pivotal trial of TV in cervical cancer that is designed to support a regulatory submission on to the FDA's accelerated approval pathway.
-
We're also enrolling a Phase 2 basket trial evaluating TV and other solid tumors where tissue factor is expressed. These include colorectal, pancreatic, non-small cell lung cancer and head and neck cancer, and we also plan to initiate a trial focused on ovarian cancer.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind